Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with
different patient populations, with inconsistent effects on cardiovascular outcomes reported.
We aimed to synthesise the available evidence by doing a systematic review and meta-
analysis of cardiovascular outcome trials of these drugs. Methods We searched MEDLINE
(via PubMed) and the Cochrane Central Register of Controlled Trials for eligible placebo …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists
and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain. We
aimed to meta-analyse the most up-to-date evidence on the cardiovascular benefits and
risks of GLP-1 receptor agonists from outcome trials in patients with type 2 diabetes.
Methods We did a meta-analysis, including new data from AMPLITUDE-O, using a random …